Andrew Pike
Novo Nordisk
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrew Pike.
Drug Metabolism and Disposition | 2006
John R. Atack; Andrew Pike; Ashley Clarke; Susan M. Cook; Bindi Sohal; Ruth M. McKernan; Gerard R. Dawson
The pharmacokinetic and pharmacodynamic (i.e., receptor occupancy) properties of L-655,708, a compound with selectivity for α5-over α1-, α2-, and α3-containing GABAA receptors, were examined in rats with the aim of developing a formulation that would give sustained (up to 6 h) and selective occupancy of α5-containing GABAA receptors suitable for behavioral studies. Standard rat pharmacokinetic analyses showed that L-655,708 has a relatively short half-life with kinetics in the brain mirroring those in the plasma. In vivo binding experiments showed that plasma concentrations of around 100 ng/ml gave relatively selective in vivo occupancy of rat brain α5-versus α1-, α2-, and α3-containing GABAA receptors. Therefore, this plasma concentration was chosen as a target to achieve relatively selective occupancy of α5-containing receptors using s.c. implantations of L-655,708 (0.4, 1.5, or 2.0 mg) formulated into tablets of various size (20 or 60 mg) containing different amounts of L-655,708 and combinations of low and high viscosity hydroxypropyl methylcellulose (LV- and HV-HPMC). The optimum formulation, 1.5 mg of L-655,708 compressed into a 60-mg tablet with 100% HV-HPMC, resulted in relatively constant plasma concentrations being maintained for at least 6 h with very little difference between Cmax concentrations (125–150 ng/ml) and plateau concentrations (100–125 ng/ml). In vivo binding experiments confirmed the selective occupancy of rat brain α5-over α1-, α2-, and α3-containing GABAA receptors.
ACS Medicinal Chemistry Letters | 2010
Wesley Peter Blackaby; Richard T. Lewis; Joanne Thomson; Andrew Jennings; Simon Charles Goodacre; Leslie J. Street; Angus Murray Macleod; Andrew Pike; Suzanne Wood; Steve Thomas; Terry A. Brown; Alison J. Smith; Gopalan V. Pillai; Sarah Almond; Martin R. Guscott; H. Donald Burns; Wai-si Eng; Christine Ryan; Jacquelynn J. Cook; Terence G. Hamill
Amalgamation of the structure-activity relationship of two series of GlyT1 inhibitors developed at Merck led to the discovery of a clinical candidate, compound 16 (DCCCyB), which demonstrated excellent in vivo occupancy of GlyT1 transporters in rhesus monkey as determined by displacement of a PET tracer ligand.
Journal of Medicinal Chemistry | 1984
Charles David Jones; Mary G. Jevnikar; Andrew Pike; Mary Kathleen Peters; Larry John Black; Allen R. Thompson; Julie F. Falcone; James A. Clemens
Journal of Pharmacology and Experimental Therapeutics | 2005
John R. Atack; Keith A. Wafford; Spencer J. Tye; Susan M. Cook; Bindi Sohal; Andrew Pike; Cyrille Sur; David Melillo; Linda J. Bristow; Fran Bromidge; Ian Ragan; Julie Kerby; Les Street; Robert W. Carling; José L. Castro; Paul Whiting; Gerard R. Dawson; Ruth M. McKernan
Journal of Medicinal Chemistry | 1992
Per Sauerberg; Preben H. Olesen; Susanne Nielsen; Svend Treppendahl; Malcolm J. Sheardown; Tage Honore; C.H. Mitch; J.S. Ward; Andrew Pike
Journal of Medicinal Chemistry | 1999
Monique B. van Niel; Ian Collins; Margaret S. Beer; Howard B. Broughton; Susan K. F. Cheng; Simon Charles Goodacre; Anne Heald; Karen L Locker; Angus Murray Macleod; Denise Morrison; Christopher Richard Moyes; Desmond O'Connor; Andrew Pike; Michael Rowley; Michael Geoffrey Neil Russell; Balbinder Sohal; Steven Thomas; Hugh M. Verrier; and Alan P. Watt; José L. Castro
Journal of Medicinal Chemistry | 2006
Simon Charles Goodacre; Leslie J. Street; David James Hallett; James Michael Crawforth; Sarah Kelly; Andrew Pate Owens; Wesley Peter Blackaby; Richard T. Lewis; Joanna Stanley; Alison J. Smith; Pushpinder Ferris; Bindi Sohal; Susan M. Cook; Andrew Pike; Nicola Brown; Keith A. Wafford; George R. Marshall; José L. Castro; John R. Atack
Journal of Medicinal Chemistry | 2002
Ian Collins; Christopher Richard Moyes; William B Davey; Michael Rowley; Frances A. Bromidge; Kathleen Quirk; John R. Atack; Ruth M. McKernan; Sally-Ann Thompson; Keith A. Wafford; Gerard R. Dawson; Andrew Pike; Bindi Sohal; Nancy N. Tsou; Richard G. Ball; José L. Castro
Journal of Medicinal Chemistry | 1993
Charles David Jones; James E. Audia; David Ernest Lawhorn; Loretta Ames Mcquaid; Blake Lee Neubauer; Andrew Pike; Pamela A. Pennington; Nancy B. Stamm; Richard E. Toomey; Kenneth Steven Hirsch
Journal of Medicinal Chemistry | 2004
Leslie J. Street; Francine Sternfeld; Richard Alexander Jelley; Austin John Reeve; Robert W. Carling; Kevin William Moore; Ruth M. McKernan; Bindi Sohal; Susan M. Cook; Andrew Pike; Gerard R. Dawson; Frances A. Bromidge; Keith A. Wafford; Guy R. Seabrook; George R. Marshall; Goplan V. Pillai; José L. Castro; and John R. Atack; Angus Murray Macleod